Showing 5381-5390 of 5621 results for "".
- Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps for ONS-5010 Clinical Strategyhttps://modernod.com/news/oncobiologics-changes-name-to-outlook-therapeutics-announces-next-steps-for-ons-5010-clinical-strategy/2476161/Oncobiologics announced several key corporate events that enhance the company’s ability to advance the development of its lead product candidate, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (AMD). These events are in c
- Takeda Shareholders Back Shire Purchasehttps://modernod.com/news/takeda-shareholders-back-shire-purchase/2479627/Shareholders of Japanese pharmaceutical company Takeda overwhelmingly voted in favor of acquiring UK-based Shire. The deal, currently valued at about $58 billion dollars, makes Takeda a top 10 global drugmaker by sales. Takeda shareholders on Wednesday voted 88 percent in favor in of thee
- MDI Biological Laboratory Scientist Receives Scientific Innovation Award for Research on AMDhttps://modernod.com/news/mdi-biological-laboratory-scientist-receives-scientific-innovation-award-for-research-on-amd/2476162/Vicki P. Losick, PhD, has been named the inaugural recipient of an award from the William Procter Scientific Innovation Fund. The award will support her research at the MDI Biological Laboratory on age-related macular degeneration (AMD). The Procter Fund was established at the MDI Biologic
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patientshttps://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher-syndrome-type-2-patients/2476165/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndrom
- Sangamo Announces Completion of TxCell Acquisitionhttps://modernod.com/news/sangamo-announces-completion-of-txcell-acquisition/2476169/Sangamo Therapeutics announced the completion of the acquisition of TxCell, which is now a subsidiary of Sangamo and has been delisted from the French stock market. “The acquisition of
- First Patient Successfully Implanted with Implandata’s Eye Pressure Sensor for Continual Glaucoma Monitoringhttps://modernod.com/news/first-patient-successfully-implanted-with-implandatas-eye-pressure-sensor-for-continual-glaucoma-monitoring/2476170/Ophthalmic medical device company Implandata Ophthalmic Products announced that the first patient in its international, multicenter, ARGOS-SC01 clinical study has been successfully implanted with its novel pressure sensor. This first-in-human clinical study is being conducted to validate the supr
- EyeCare Partners Acquires Holcomb Laser Centerhttps://modernod.com/news/eyecare-partners-acquires-holcomb-laser-center/2479632/EyeCare Partners (ECP) furthered its expansion into the Alabama ophthalmology market with the acquisition of Dr. William Holcomb’s Cullman, Alabama-based Holcomb Laser Center, according to an announcement from EyeCare Partners, as reported in VisionMonday. Terms of the deal were not disclo
- Envision Conference to Split in Two in 2019https://modernod.com/news/envision-conference-to-split-in-two-in-2019/2479634/For the first time since its inception in 2006, Envision Conference will be split into two events for the upcoming year: Envision Conference East, March 22-23, 2019 at the University of Alabama at Birmingham in Birmingham, Alabama; and Envision Conference West, October 5-6, 2019 at the College of
- Dry Eye Symptom Screens Show Modest Accuracyhttps://modernod.com/news/dry-eye-symptom-screens-show-modest-accuracy/2479636/In head-to-head comparisons, two of five dry eye screens showed a statistically significant ability to detect signs of the disorder, but all demonstrated relatively modest diagnostic accuracy, researchers say, according to a Reuters report
- Eyenovia Publishes PG21 Phase 2 Trial Results Examining IOP Lowering Effect and Patient Usabilityhttps://modernod.com/news/eyenovia-publishes-pg21-phase-2-trial-results-examining-iop-lowering-effect-and-patient-usability/2479637/Eyenovia announced that the full results of its phase 2 PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-